The use of the synthetic analogue of leucin-encephaline in complementary therapy of dogs with chronic pancreatitis
DOI:
https://doi.org/10.31548/ujvs2020.01.006Abstract
Abstract. A review of the problem of treating dogs for pancreatitis with peptide drugs is presented. The main attention is paid to the analysis of the use of somatostatin, octreotide and the synthetic analogue of leucine-enkephalin – dalargin. Despite numerous studies of the therapeutic effects of these agents for acute pancreatitis and pancreatic necrosis in humane medicine, there is no definitive answer about their efficacy in dogs due to the lack of work performed in accordance with the criteria of evidence-based medicine.
The use of dalargin in the complex therapy of dogs with chronic pancreatitis, eliminates or reduces pain and dyspeptic phenomena, contributes to the onset of positive changes at the same time a number of positive changes in the functional state of the pancreas manifested by decreased serum amylase activity 3 times, pancreatic lipase in the 1,9 times.
Studies carried out on dogs, patients with chronic pancreatitis, it is determined that against the background of treatment of synthetic analogue Leukin-enkefaline – Dalagin. The intensity of pain decreased (up to 5 days in 90% of patients), decreased amylase and pancreatic lipase activity and TBK-active product (malonic dialdehyde, MDA) in their blood serum. Ultrasound showed data on the reduction of pancreatic edema, in 7 sick dogs, its sizes were restored to indicators in healthy animals.
Keywords: chronic pancreatitis, acute pancreatitis, dogs, dalargin, serum amylase, pancreatic lipase
References
Heinrich, S., Schafer, V., Rousson, V., Clavien, P. A. (2006). Evidence - based treatment of acute pancreatitis: a look at established paradigms. Annals Surgery, 243(2): 154-168.
https://doi.org/10.1097/01.sla.0000197334.58374.70
Gelfand, B. R., Burnevich, S. Z., Grojzik, K. L. (1998). Preparaty somatostatina v neotlozhnoj pankreatologii: sostoyanie i perspektiva. Vestnik intensivnoj terapii, 3:19-24. (In Russian)
Choi, T. K., Mok, F., Zhan, W., Fan, S. T., Wong, J. (1989). Somatostatin in the treatment of acute pancreatitis: a prospective randomized controlled trial. British Medical Journal, Gut., 30: 223-227. https://doi.org/10.1136/gut.30.2.223
Makhija, R., Kingsnorth, A. N. (2002). Cytokine storm in acute pancreatitis. Journal Hepatobiliary Pancreatic Surgery, 9:401-410.
https://doi.org/10.1007/s005340200049
Li, J., Wang, R., Tang, C. (2011). Somatostatin and octreotide on the treatment of acute pancreatitis - basic and clinical studies for three decades. Current Pharmaceutical Design, 17: 1594-1601.
https://doi.org/10.2174/138161211796196936
Uhl, W., Warshaw, A., Imrie, C. (2002). IAP Guidelines for the surgical management of acute pancreatitis. Pancreatology, 2:565-573. https://doi.org/10.1159/000067684
Bulgakov, S. A. (2015). Agonisty opiatnyh receptorov v gastroenterologicheskoj praktike. Dokazatelnaya gastroenterologiya, 4(1):14-18.
https://doi.org/10.17116/dokgastro201541-214-18
Vasilev A. A. (2010). Ocenka effektivnosti oktreotida v kompleks konservativnogo lecheniya ostrogo pankreatita u sobak i koshek. Avtoreferat dis. kandidata veterinarnyh nauk, M., 201. (In Russian).
Zohirov, A. I., Mihajlov, K. A., Sargsyan, E. G., Sein, O. B. (2016). Vliyanie sintenticheskogo analoga opioidnyh peptidov dalargina na antioksidantnyj status sobak. Vestnik Kurskoj gosudarstvennoj selskohozyajstvennoj akademii, 9: 156-169. (In Russian).
Chaturvedi, K. (2003). Opioid peptides, opioid receptors and mechanism of down regulation. Indian Journal Experimental Biology, 41(1): 5-13.
Lyashev, Y. D. (2002). Effect of opioid peptides on bone tissue reparative regeneration. Archives of Pathology, 64(1): 6-8.
Clayton, H., Flatz, L., Vollenweider-Roten, S., Schoepfer, A., Gilliet, M., Conrad, C. (2013). Anti-TNF therapy in the treatment of psoriasis in a patient with acute-on-chronic pancreatitis. Dermatology, 227:193-196. https://doi.org/10.1159/000351714
Oruc, N., Ozutemiz, A. O., Yukselen, V., Nart, D., Celik, H. A., Yuce, G., Batur, Y. (2004). Infliximab: a new therapeutic agent in acute pancreatitis? Pancreas, 28: e1-e8.
https://doi.org/10.1097/00006676-200401000-00020
Zheng, L., Xue, J., Jaffee, E. M., Habtezion, A. (2013). Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology, 144: 1230-1240. https://doi.org/10.1053/j.gastro.2012.12.042
Habtezion, A., Kwan, R., Yang, A.L., Morgan, M. E., Akhtar, E., Wanaski. S. P., Collins, S. D., Butcher, E. C., Kamal, A., Omary, M. B. (2011). Heme oxygenase-1 is induced in peripheral blood mono- nuclear cells of patients with acute pancreatitis: a potential therapeutic target. American Journal Physioogyl Gastrointestinal Liver Physiology, 300: 12-20. https://doi.org/10.1152/ajpgi.00231.2010
Downloads
Published
Issue
Section
License
Relationship between right holders and users shall be governed by the terms of the license Creative Commons Attribution – non-commercial – Distribution On Same Conditions 4.0 international (CC BY-NC-SA 4.0):https://creativecommons.org/licenses/by-nc-sa/4.0/deed.uk
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
